

**FORMATO EUROPEO
PER IL CURRICULUM
VITAE**



INFORMAZIONI PERSONALI

Nome
Indirizzo
Telefono
Fax
E-mail

Nazionalità

Data di nascita

PACCAPELO ALEXANDRO

ESPERIENZA LAVORATIVA

- Date (da – a)
- Nome e indirizzo del datore di lavoro
- Tipo di azienda o settore
- Tipo di impiego
- Principali mansioni e responsabilità

Dal 9 dicembre 2019

Azienda Ospedaliero-Universitaria di Bologna – Policlinico Sant’Orsola-Malpighi, Via Albertoni 15, Bologna

Sanitario

Analisi Statistiche, data management

Statistico e data manager – Radiologia-Golfieri - Policlinico Sant’Orsola-Malpighi

- Date (da – a)
- Nome e indirizzo del datore di lavoro
- Tipo di azienda o settore
- Tipo di impiego
- Principali mansioni e responsabilità

2 Settembre 2013 – 6 dicembre 2019

AUSL Bologna, Via Castiglione 29, Bologna

Sanitario

Analisi Statistiche, data management

Statistico e data manager - Ufficio Sperimentazioni Cliniche Oncologia - Ospedale Bellaria

- Date (da – a)
- Nome e indirizzo del datore di lavoro
- Tipo di azienda o settore
- Tipo di impiego
- Principali mansioni e responsabilità

Febbraio 2012 – Giugno 2013

Università di Bologna - Dipartimento di Scienze Mediche e Chirurgiche
Policlinico S. Orsola-Malpighi, Via Massarenti, 9 - 40138 Bologna

Istruzione/Sanitario

Supporto alla ricerca, Analisi Statistiche

Laureato Frequentatore Università di Bologna

- Date (da – a)
- Nome e indirizzo del datore di lavoro
- Tipo di azienda o settore
- Tipo di impiego
- Principali mansioni e responsabilità

Marzo 2009 – Dicembre 2010

Steer Davies Gleave, via Ugo Bassi 7, Bologna

Consulenza – Settore Trasporti

Analista – Modellista

Supporto

- Date (da – a)

Giugno 2002 – Luglio 2002

- Nome e indirizzo del datore di lavoro
- Tipo di azienda o settore
- Tipo di impiego
- Principali mansioni e responsabilità

Arpa, via Po 5, Bologna

Azienda Pubblica - Ambiente
Manutenzione Sito Web

ISTRUZIONE E FORMAZIONE

- Date (da – a) Novembre 2011 – Marzo 2012
- Nome e tipo di istituto di istruzione o formazione Master in Risk Management & Capital Allocation presso Captha srl, Milano
- Principali materie / abilità professionali oggetto dello studio Gestione dei rischi finanziari (credito, operativo, interesse, liquidità), regolamentazione del capitale, Basilea II, Solvency I)
- Qualifica conseguita Master
- Livello nella classificazione nazionale (se pertinente)

- Date (da – a) Ottobre 2007 – 14 Dicembre 2010
- Nome e tipo di istituto di istruzione o formazione Laurea in Scienze Statistiche ed Economiche presso l'Università Alma Mater Studiorum di Bologna
- Principali materie / abilità professionali oggetto dello studio Scienze Statistiche – Ricerche di Mercato
- Qualifica conseguita Titolo della tesi: "Modelli Logit: la previsione della domanda di sosta per la costruzione di nuovi parcheggi"
- Livello nella classificazione nazionale (se pertinente) Laurea Specialistica (classe 91/S)
Laurea con voti 105/110

- Date (da – a) Ottobre 2003 – 1 Marzo 2007
- Nome e tipo di istituto di istruzione o formazione Laurea in Statistica Impresa e Mercati presso l'Università Alma Mater Studiorum di Bologna
- Principali materie / abilità professionali oggetto dello studio Scienze Statistiche – Ricerche di Mercato
- Qualifica conseguita Titolo della tesi: "Analisi di segnali da un elettrocardiogramma"
- Livello nella classificazione nazionale (se pertinente) Laurea Triennale (classe 37)
Laurea con voti 101/110

- Date (da – a) Settembre 1999 – Giugno 2003
- Nome e tipo di istituto di istruzione o formazione Maturità scientifica presso il Liceo Scientifico Statale "A. B. Sabin", Bologna
- Principali materie / abilità professionali oggetto dello studio Piano Nazionale d'Informatica (intero quinquennio)
- Qualifica conseguita Diploma scientifico
- Livello nella classificazione nazionale (se pertinente) Maturità scientifica con voti 75/100

PRIMA LINGUA

ITALIANO

ALTRE LINGUE

INGLESE

- Capacità di lettura INTERMEDIO
- Capacità di scrittura INTERMEDIO
- Capacità di espressione orale INTERMEDIO

**CAPACITÀ E COMPETENZE
TECNICHE**

*Con computer, attrezzature specifiche,
macchinari, ecc.*

Windows, pacchetto Office, R, SPSS, STATA, Linguaggio C livello base
European Computer Driving Licence – Core Level
Idoneità linguistica inglese B1

PATENTE O PATENTI

Patente B

ALTRE CAPACITÀ E COMPETENZE

*Competenze non precedentemente
indicate.*

Pubblicazioni:

Percutaneous Management of Postoperative Bile Leak After Hepato-Pancreato-Biliary Surgery: A Multi-Center Experience

Cristina Mosconi, Marco Calandri, Mariateresa Mirarchi, Giulio Vara, Andrea Doriguzzi Breatta, Alberta Cappelli, Nicolò Brandi, Alexandro Paccapelo, Caterina De Benedittis, Claudio Ricci, Mirian Sassone, Matteo Ravaioli, Marco Fronda, Alessandro Cucchetti, Enrico Petrella, Riccardo Casadei, Matteo Cescon, Renato Romagnoli, Giorgio Ercolani, Emanuela Giampalma, Dorico Righi, Paolo Fonio, Rita Golfieri
(2021). Hepato-Pancreato-Biliary journal – Accepted Manuscript

Retrospective european multicentric evaluation of selective transarterial chemoembolisation with and without balloon-occlusion in patients with hepatocellular carcinoma: a propensity score matched analysis

Rita Golfieri, Mario Bezzi, Gontran Verset, Fabio Fucilli, Cristina Mosconi, Alberta Cappelli, Alexandro Paccapelo, Pierleone Lucatelli, Nicolas Magand, Agnes Rode, Thierry De Baere.
(2021). CardioVascular and Interventional Radiology – Accepted Manuscript

Expected and non-expected immune-related adverse events detectable by CT.

Federica Ciccarese, Alberto Piccinino, Stefano Brocchi, Caterina Balacchi, Filippo Gustavo Dall'Olio, Francesco Massari, Karim Rihawi, Alexandro Paccapelo, Andrea Ardizzoni, Rita Golfieri.

European Journal of Radiology. Published: February 24, 2021
DOI: <https://doi.org/10.1016/j.ejrad.2021.109617>

Diagnostic Accuracy of North America Expert Consensus Statement on Reporting CT Findings in Patients with Suspected COVID-19 Infection: An Italian Single Center Experience.

Ciccarese, F., Coppola, F., Spinelli, D., Galletta, G. L., Lucidi, V., Paccapelo, A., De Benedittis, C., Balacchi, C., & Golfieri, R.

(2020). Radiology. Cardiothoracic Imaging, 2(4), e200312.
<https://doi.org/10.1148/ryct.2020200312>

MGMT methylation as a prognostic factor in IDH wild type anaplastic gliomas.

Franceschi, E., Tosoni, A., Di Nunno, V., Mura, A., Asloli, S., Pession, A., Agati, R., Paccapelo, A., Bartolini, S., Brandes, A. A.

(2020). DOI: 10.1200/JCO.2020.38.15_suppl.2523 Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 2523-2523. Published online May 25, 2020.

Histopathological grading affects survival in patients with IDH-mutant grade II and grade III diffuse gliomas.

Franceschi E, Tosoni A, Bartolini S, Minichillo S, Mura A, Asloli S, Bartolini D, Gardiman M, Gessi M, Ghimenton C, Giangaspero F, Lanza G, Marucci G, Novello M, Silini EM, Zunarelli E, Paccapelo A, Brandes AA.

Eur J Cancer. 2020 Sep;137:10-17. doi: 10.1016/j.ejca.2020.06.018. Epub 2020 Jul 26.
PMID: 32721633

Concordance between RTOG and EORTC prognostic criteria in low-grade gliomas.

Franceschi E, Mura A, Lamberti G, De Biase D, Tosoni A, Di Battista M, Argento C, Visani M, Paccapelo A, Bartolini S, Brandes AA.

Future Oncol. 2019 Aug;15(22):2595-2601. doi: 10.2217/fo-2019-0093. Epub 2019 Jul 24.

PMID: 31339049

Survival outcomes in glioma patients with noncanonical IDH mutations: Beyond diagnostic improvements.

Enrico Franceschi, Dario De Biase, Annalisa Pession, Alicia Tosoni, Alexandro Paccapelo, Michela Visani, Giovanni Tallini, Chiara Maria Argento, Benedetta Urbini, Stefania Bartolini, Alba Ariela Brandes.

May 2019 *Journal of Clinical Oncology* 37(15_suppl):2028-2028

DOI: 10.1200/JCO.2019.37.15_suppl.2028

Effect of grade on survival in IDH-mutant grade II and grade III gliomas.

Giuseppe Lamberti, Enrico Franceschi, Alicia Tosoni, Antonella Mura, Alexandro Paccapelo, Maria Pia Foschini, Sofia Asioli, Dario De Biase, Annalisa Pession, Giovanni Tallini, Stefania Bartolini, Felice Giangaspero, Alba Ariela Brandes.

May 2019 *Journal of Clinical Oncology* 37(15_suppl):2036-2036

DOI: 10.1200/JCO.2019.37.15_suppl.2036

IDH1 polymorphism G105G (rs11554137) as a prognostic factor in gliomas.

Enrico Franceschi, Dario De Biase, Alicia Tosoni, Alexandro Paccapelo, Giorgia Acquaviva, Annalisa Pession, Giovanni Tallini, Chiara Maria Argento, Stefania Bartolini, Alba Ariela Brandes.

May 2019 *Journal of Clinical Oncology* 37(15_suppl):e14734-e14734

DOI: 10.1200/JCO.2019.37.15_suppl.e14734

Adjuvant chemotherapy to improve survival in average-risk adult medulloblastoma patients: Long-term results.

Giuseppe Lamberti, Enrico Franceschi, Alicia Tosoni, Santino Minichillo, Monica Di Battista, Alexandro Paccapelo, Carmelo Sturiale, Maurizio Mascarin, Barbara Masotto, Lorenzo Volpin, Stefania Bartolini, Felice Giangaspero, Alba Ariela Brandes.

May 2019 *Journal of Clinical Oncology* 37(15_suppl):2037-2037

DOI: 10.1200/JCO.2019.37.15_suppl.2037

BRAF V600E Status and Stimulated Thyroglobulin at Ablation Time Increase Prognostic Value of American Thyroid Association Classification Systems for Persistent Disease in Differentiated Thyroid Carcinoma.

Repaci A, Vicennati V, Paccapelo A, Cavicchi O, Salituro N, Monari F, de Biase D, Tallini G, Altimari A, Gruppioni E, Fiorentino M, Pagotto U.

Int J Endocrinol. 2019 Apr 7;2019:3081497. doi: 10.1155/2019/3081497. eCollection 2019.

PMID: 31093278 Free PMC article.

Postsurgical Approaches in Low-Grade Oligodendroglioma: Is Chemotherapy Alone Still an Option?

Franceschi E, Tosoni A, De Biase D, Lamberti G, Danieli D, Pizzolitto S, Zunarelli E, Visani M, Di Oto E, Mura A, Minichillo S, Scafati C, Asioli S, Paccapelo A, Bartolini S, Brandes AA.

Oncologist. 2019 May;24(5):664-670. doi: 10.1634/theoncologist.2018-0549. Epub 2019 Feb 18.

PMID: 30777895 Free PMC article.

The role of clinical and molecular factors in low-grade gliomas: what is their impact on survival?

Franceschi E, Mura A, De Biase D, Tallini G, Pession A, Foschini MP, Danieli D, Pizzolitto S, Zunarelli E, Lanza G, Bartolini D, Silini EM, Visani M, Di Oto E, Tosoni A, Minichillo S, Lamberti G, Lanese A, Paccapelo A, Bartolini S, Brandes AA.

Future Oncol. 2018 Jul;14(16):1559-1567. doi: 10.2217/fon-2017-0634. Epub 2018 Jun 25.

PMID: 29938525

Temozolomide rechallenge in recurrent glioblastoma: when is it useful?

Franceschi E, Lamberti G, Visani M, Paccapelo A, Mura A, Tallini G, Pession A, De Biase D, Minichillo S, Tosoni A, Di Battista M, Cubeddu A, Bartolini S, Brandes AA.

Future Oncol. 2018 May;14(11):1063-1069. doi: 10.2217/fon-2017-0681. Epub 2018 May 9.

PMID: 29741106

Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab?

Franceschi E, Lamberti G, Paccapelo A, Di Battista M, Genestreti G, Minichillo S, Mura A, Bartolini S, Agati R, Brandes AA.

J Neurooncol. 2018 Sep;139(2):383-388. doi: 10.1007/s11060-018-2873-x. Epub 2018 Apr 18.

PMID: 29671196

The Prognostic Roles of Gender and O6-Methylguanine-DNA Methyltransferase Methylation Status in Glioblastoma Patients: The Female Power.

Franceschi E, Tosoni A, Minichillo S, Depenni R, Paccapelo A, Bartolini S, Michiara M, Pavesi G, Urbini B, Crisi G, Cavallo MA, Tosatto L, Dazzi C, Biasini C, Pasini G, Balestrini D, Zanelli F, Ramponi V, Fioravanti A, Giombelli E, De Biase D, Baruzzi A, Brandes AA; PERNO Study Group.

World Neurosurg. 2018 Apr;112:e342-e347. doi: 10.1016/j.wneu.2018.01.045. Epub 2018 Jan 11.

PMID: 29337169

Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study.

Brandes AA, Finocchiaro G, Zagonel V, Reni M, Fabi A, Caserta C, Tosoni A, Eoli M, Lombardi G, Clavarezza M, Paccapelo A, Bartolini S, Cirillo L, Agati R, Franceschi E.

Oncotarget. 2017 Feb 25;8(33):55575-55581. doi: 10.18632/oncotarget.15735. eCollection 2017 Aug 15. PMID: 28903444

Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria.

Visani M, Acquaviva G, Marucci G, Paccapelo A, Mura A, Franceschi E, Grifoni D, Pession A, Tallini G, Brandes AA, de Biase D.

J Neurooncol. 2017 Jul 26. doi: 10.1007/s11060-017-2571-0. [Epub ahead of print]

PMID: 28748342

Low grade glioma patients with IDH mutation and 1p19q codeletion: To treat or not to treat?

Enrico Franceschi, Dario De Biase, Alexandro Paccapelo, Antonella Mura, Alicia Tosoni, Stefania Bartolini, Giovanni Tallini, Annalisa Pession, Daniela Danielli, Sabrina Rossi, Daniela Bartolini, Marina Paola Gardiman, Lorenzo Volpin, Vania Ramponi, Antonio Fioravanti, Maria Pia Foschini, Enrico Di Olo, Santino Minichillo, Stefano Pizzolitto, and Alba Ariela Brandes
Journal of Clinical Oncology 2017 35:15_suppl, 2017-2017

The percentage of Epidermal Growth Factor Receptor (EGFR)-mutated neoplastic cells correlates to response to tyrosine kinase inhibitors in lung adenocarcinoma.

de Biase D, Genestreti G, Visani M, Acquaviva G, Di Battista M, Cavallo G, Paccapelo A, Cancellieri A, Trisolini R, Degli Esposti R, Bartolini S, Pession A, Tallini G, Brandes AA.

PLoS One. 2017 May 16;12(5):e0177822. doi: 10.1371/journal.pone.0177822. eCollection 2017. PMID: 28520821

Role of MGMT Methylation Status at Time of Diagnosis and Recurrence for Patients with Glioblastoma: Clinical Implications.

Brandes AA, Franceschi E, Paccapelo A, Tallini G, De Biase D, Ghimenton C, Danielli D, Zunarelli E, Lanza G, Silini EM, Sturiale C, Volpin L, Servadei F, Talacchi A, Fioravanti A, Pia Foschini M, Bartolini S, Pession A, Ermani M.

Oncologist. 2017 Mar 8. pii: theoncologist.2016-0254. doi: 10.1634/theoncologist.2016-0254. PMID: 28275120

The role of clinical characteristics in low grade gliomas patients in the era of molecular biomarkers: a study from gruppo italiano cooperativo di neuro-oncologia (gicno).

Enrico Franceschi, Dario De Biase, Annalisa Pession, Alexandro Paccapelo, Michele Reni, Anna Mandrioli, Daniela Danielli, Stefania Bartolini, Gianluca Marucci, Laura Lombardo, Benedetta Urbini, Maria Michiara, Alicia Tosoni, Giovanni Tallini, Claudia Biasini, Alba Ariela Brandes.
Neuro-Oncology, 18, suppl 6, vi1-vi1, 2016, Oxford University Press.

Clinical risk or molecular risk: What matters in low grade gliomas? A study from the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

E Franceschi, D De Biase, A Paccapelo, M Reni, A Mura, G Tallini, C Bortolotti, L Volpin, G Marucci, L Cirillo, A Pession, C Ghimenton, R Poggi, S Bartolini, L Albini Riccioli, A Tosoni, C Degli Esposti, D Danielli, G Genestreti, AA Brandes

Annals of Oncology, 27, suppl 6, 323O, 2016, Eur Soc Med Oncology

Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study.

Franceschi E, Depenni R, Paccapelo A, Ermani M, Faedi M, Sturiale C, Michiara M, Servadei F, Pavesi G, Urbini B, Pisanello A, Crisi G, Cavallo MA, Dazzi C, Biasini C, Bertolini F, Mucciarini

C, Pasini G, Baruzzi A, Brandes AA; PERNO Study Group.
J Neurooncol. 2016 May;128(1):157-62. doi: 10.1007/s11060-016-2093-1. Epub 2016 Mar 4.
PMID: 26943851

Adjuvant chemotherapy in adult medulloblastoma: is it an option for average-risk patients?
Franceschi E, Bartolotti M, Paccapelo A, Marucci G, Agati R, Volpin L, Danielli D, Ghimenton C,
Gardiman MP, Sturiale C, Poggi R, Mascarin M, Balestrini D, Masotto B, Brandes AA.
J Neurooncol. 2016 Jun;128(2):235-40. doi: 10.1007/s11060-016-2097-x. Epub 2016 Mar 3.
PMID: 26940908

Patient outcomes following second surgery for recurrent glioblastoma.
Brandes AA, Bartolotti M, Tosoni A, Poggi R, Bartolini S, Paccapelo A, Bacci A, Ghimenton C,
Pession A, Bartolotti C, Zucchelli M, Galzio R, Talacchi A, Volpin L, Marucci G, de Biase D,
Pizzolitto S, Danielli D, Ermani M, Franceschi E.
Future Oncol. 2016 Apr;12(8):1039-44. doi: 10.2217/fon.16.9. Epub 2016 Feb 16.
PMID: 26880307

Time to response (TTR) and early tumor shrinkage (ETS) in recurrent glioblastoma patients
treated with bevacizumab: an exploratory analysis of the prospective randomized AVAREG
(ML25739) phase II study.
E Franceschi, G Finocchiaro, V Zagonel, M Reni, A Fabi, C Caserta, M Clavarezza, E Maiello, G
Carteni, G Rosti, R Agati, A Tosoni, E Proietti, A Paccapelo, AA Brandes.
Annals of Oncology,26,suppl 6,vi-vi,2015,Eur Soc Med Oncology

Revisiting the role of pathological analysis in transarterial chemoembolization-treated
hepatocellular carcinoma after transplantation.
Vasuri F, Malvi D, Rosini F, Baldin P, Fiorentino M, Paccapelo A, Ercolani G, Pinna AD, Golfieri
R, Morselli-Labate AM, Grigioni WF, D'Errico-Grigioni A.
World J Gastroenterol. 2014 Oct 7;20(37):13538-45. doi: 10.3748/wjg.v20.i37.13538.
PMID: 25309084

Fetal head-symphysis distance and mode of delivery in the second stage of labor.
Youssef A, Maroni E, Cariello L, Bellussi F, Montaguti E, Salsi G, Morselli-Labate AM,
Paccapelo A, Rizzo N, Pilu G, Ghi T.
Acta Obstet Gynecol Scand. 2014 Oct;93(10):1011-7. doi: 10.1111/aogs.12454. Epub 2014 Aug
13. PMID: 25040777

Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-
secreting or associated with intermediate phenotype or subclinical Cushing's syndrome: a 15-
year retrospective study.
Di Dalmazi G, Vicennati V, Garelli S, Casadio E, Rinaldi E, Giampalma E, Mosconi C, Golfieri R,
Paccapelo A, Pagotto U, Pasquali R.
Lancet Diabetes Endocrinol. 2014 May;2(5):396-405. doi: 10.1016/S2213-8587(13)70211-0.
Epub 2014 Jan 29.
PMID: 24795253

The descent of the fetal head is not modified by mobile epidural analgesia: a controlled
sonographic study.
Maroni E, Youssef A, Rainaldi MP, Valentini MV, Turchi G, Morselli-Labate AM, Paccapelo A,
Pacella G, Contro E, Arcangeli T, Rizzo N, Pilu G, Ghi T.
Acta Obstet Gynecol Scand. 2014 May;93(5):512-6. doi: 10.1111/aogs.12370.
PMID: 24754606

Salmonella gastroenteritis during childhood is a risk factor for irritable bowel syndrome in
adulthood.
Cremon C, Stanghellini V, Pallotti F, Fogacci E, Bellacosa L, Morselli-Labate AM, Paccapelo A,
Di Nardo G, Cogliandro RF, De Giorgio R, Corinaldesi R, Barbara G.
Gastroenterology. 2014 Jul;147(1):69-77. doi: 10.1053/j.gastro.2014.03.013. Epub 2014 Mar 20.
PMID: 24657623

Sonographic pattern of fetal head descent: relationship with duration of active second stage of
labor and occiput position at delivery.
Ghi T, Maroni E, Youssef A, Morselli-Labate AM, Paccapelo A, Montaguti E, Rizzo N, Pilu G.
Ultrasound Obstet Gynecol. 2014 Jul;44(1):82-9. doi: 10.1002/uog.13324. Epub 2014 May 28.
PMID: 24496823

Agreement between two- and three-dimensional methods for the assessment of the fetal head-symphysis distance in active labor.

Youssef A, Bellussi F, Montaguti E, Maroni E, Salsi G, Morselli-Labate AM, Paccapelo A, Rizzo N, Pilu G, Ghi T.

Ultrasound Obstet Gynecol. 2013 Sep 4. doi: 10.1002/uog.13204.

PMID: 24006290

Clinical Predictors Of Persistent Disease In Patients With Brafv600e Mutated Papillary Thyroid Cancer (ptc) - A Repaci, V Vicennati, A Paccapelo, O Cavicchi, F Monari, R Mazzarotto, G Tallini, A Altimari, E Gruppioni, M Fiorentino, R Pasquali - European Thyroid Journal

Interobserver agreement of PQ elastography in the evaluation of liver elasticity in three operators with different expertise - C De Molo, E Fiorini, S Righi, E Mazzotta, A Paccapelo, F Conti, L Brodosi, P Andreone, C Serra - Ultraschall in der Medizin-European Journal of Ultrasound

Accuracy and reproducibility of shear wave elastography assessing liver fibrosis - C De Molo, A Ignee, XW Cui, E Fiorini, A Paccapelo, F Tovoli, S Righi, C Serra, CF Dietrich - Ultraschall in der Medizin-European Journal of Ultrasound

Androgen Profiling by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) in Healthy Normal-Weight Ovulatory and Anovulatory Late Adolescent and Young Women. Fanelli F, Gambineri A, Belluomo I, Repaci A, Di Lallo VD, Di Dalmazi G, Mezzullo M, Prontera O, Cuomo G, Zanotti L, Paccapelo A, Morselli-Labate AM, Pagotto U, Pasquali R.

J Clin Endocrinol Metab. 2013 Jun 18.

PMID: 23780369

Homeopathic medicine for acute cough in upper respiratory tract infections and acute bronchitis: A randomized, double-blind, placebo-controlled trial.

Zanasi A, Mazzolini M, Tursi F, Morselli-Labate AM, Paccapelo A, Lecchi M.

Pulm Pharmacol Ther. 2013 May 25. doi:pil: S1094-5539(13)00125-9.

10.1016/j.pupt.2013.05.007.

PMID: 23714686

Tubeless procedure reduces hospitalization and pain after percutaneous nephrolithotomy: results of a multivariable analysis.

Garofalo M, Pultrone CV, Schiavina R, Brunocilla E, Sanguedolce F, Borghesi M, Rocca C, Del Prete C, Morselli-Labate AM, Paccapelo A, Martorana G.

Urolithiasis. 2013 Apr 30.

PMID: 23632910

Intrapartum transperineal ultrasound assessment of the fetal head progression in the active second stage and the mode of delivery.

Ghi T, Youssef A, Maroni E, Arcangeli T, De Musso F, Bellussi F, Nanni M, Giorgetta F, Morselli-Labate AM, Iammarino MT, Paccapelo A, Cariello L, Rizzo N, Pilu G.

Ultrasound Obstet Gynecol. 2013 Jan 3. doi: 10.1002/uog.12379.

PMID: 23288706

The fetal head-symphysis distance: a simple and reliable ultrasound index of fetal station in labor.

Youssef A, Maroni E, Ragusa A, De Musso F, Salsi G, Iammarino MT, Paccapelo A, Rizzo N, Pilu G, Ghi T.

Ultrasound Obstet Gynecol. 2012 Nov 5. doi: 10.1002/uog.12335.

PMID: 23124698

Colonic mucosal mediators from patients with irritable bowel syndrome excite enteric cholinergic motor neurons.

Balestra B, Vicini R, Cremon C, Zocchi L, Dothel G, Vasina V, De Giorgio R, Paccapelo A, Pastoris O, Stanghellini V, Corinaldesi R, De Ponti F, Tonini M, Barbara G.

Neurogastroenterol Motil. 2012 Sep 2. doi: 10.1111/nmo.12000.

PMID: 22937879

Mortality in long-term follow-up patients with progressively increased patterns of subclinical cortisol hypersecretion.

Di Dalmazi G, Vicennati V, Paccapelo A, Pagotto U, Pasquali R.
Endocrine Abstracts (2013) 32 P16 - DOI:10.1530/endoabs.32.P16 - Abstract in 15th European Congress of Endocrinology, Copenhagen, Denmark, 27 April 2013 - 01 May 2013.

Acute Salmonella Gastroenteritis Occurring Early in Life but Not in Adulthood Is a Risk Factor for Post-Infectious Irritable Bowel Syndrome (PI-IBS) in the Long Term.

Cremon C, Pallotti F, Morselli-Labate AM, Paccapelo A, Bellacosa L, Marcellini MM, De Giorgio R, Corinaldesi R, Stanghellini V, Barbara G.

Abstract - May 2013 - Gastroenterology Vol. 144, Issue 5, Supplement 1, Page S-724.

Three Dimensional Contrast Enhanced Ultrasonography vs. Magnetic Resonance Imaging in The Diagnosis of IPMN of the Pancreas.

Serra C, Calculli L, Imbrogno A, Fabbri D, Ferroni F, Paccapelo A, Casadei R, Pezzilli R.

JOP. Journal of the Pancreas Vol 13. No 5S (2012) -Abstract in AISP - 36th National Congress. Bologna, Italy. October 4-6, 2012.

Partecipazione come study coordinator agli studi:

BGB-A317-301 - Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy and Safety of BGB-A317 versus Sorafenib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma

CA209-227 - Studio di fase III in aperto, randomizzato, con nivolumab o nivolumab più ipilimumab rispetto a una doppietta chemioterapica a base di platino in soggetti affetti da carcinoma polmonare non a piccole cellule (Non-Small Cell Lung Cancer, NSCLC) naïve alla chemioterapia, di stadio IV o recidivante.

CA209-9DX - Studio di fase 3, randomizzato, in doppio cieco di Nivolumab adiuvante rispetto al placebo per pazienti con carcinoma epatocellulare che sono ad alto rischio di recidiva dopo resezione o ablazione epatica curativa

E7080-J081-116 - An open-label phase 1b trial of Levatinib plus Pembrolizumab in subjects with Hepatocellular carcinoma.

J2G-MC-JZJC - A multicenter, randomized, open-label, phase III trial comparing LOXO-292 to platinum based and pemetrexed with or without pembrolizumab as initial therapy of advanced or metastatic RET fusion-positive non small cell lung cancer

LEAP-011 - Studio di fase 3, randomizzato, in doppio cieco, per confrontare l'efficacia e la sicurezza di Pembrolizumab (MK-3475) in combinazione con Lenvatinib (E7080 / MK-7902) versus Pembrolizumab e Placebo come trattamento di prima linea per il carcinoma uroteliale localmente avanzato o metastatico in pazienti non eleggibili al cisplatino, il cui tumore esprime PD-L1, e in pazienti non eleggibili a qualsiasi altra chemioterapia contenente platino, indipendentemente dall'espressione di PD-L1

005-00 - An open label, randomized phase 3 study of MK-6482 versus everolimus in participants with advanced renal cell carcinoma that has progressed after prior PD-1/L1 and VEGF-targeted therapies*

KEYNOTE 641 - A phase 3, randomized, double-blind trial of Pembrolizumab plus Enzalutamide versus placebo plus enzalutamide in participants with metastatic castration resistant prostate cancer

010-00-KEYLYNK-010 - A phase 3, randomized open label study of Pembrolizumab plus olaparib versus Abiraterone acetate or Enzalutamide in participants with metastatic castration-resistant prostate cancer who are unselected for homologous recombinant repair defects and have failed prior treatment with one Next-generation Hormonal Agent (NHA) and chemotherapy

ARRAY-818-202 - Studio di Fase II in aperto con Encorafenib + Binimetinib in pazienti affetti da carcinoma polmonare non a piccole cellule portatori di mutazione BRAF V600E

SEQ-HN - A 2 cohort, non-comparative, pivotal study evaluating the efficacy of tipifamib in

patients with head and neck squamous cell carcinoma (HNSCC) with HRAS mutations (AIM-HN) and the impact of HRAS mutations on response to first line systemic therapies for HNSCC

AP26113-13-301 - A phase 3, multicenter, open-label study of Brigatinib (AP26113) versus crizotinib in patients with ALK-positive advanced lung cancer.

E7080-J081-116 - An open-label phase 1b trial of Levatinib plus Pembrolizumab in subjects with Hepatocellular carcinoma.

CLEAR E7080-G000-307 - Sperimentazione di fase 3 multicentrica, in aperto, randomizzata, per Confrontare l'efficacia e la sicurezza di Lenvatinib in combinazione con Everolimus o pembrolizumab rispetto a sunitinib in monoterapia nel trattamento di prima linea di soggetti con carcinoma a cellule Renali avanzato

WO41994 - A phase III, multicenter, randomized, open-label study to evaluate the efficacy and safety of Atezolizumab given in combination with Cabozantinib versus cabozantinib alone in patients with inoperable locally advanced or metastatic renal cell carcinoma who experienced radiographic tumor progression during or after immune checkpoint inhibitor treatment

MK3475-966 KEYNOTE 966 - "Studio Randomizzato di Fase 3, in doppio cieco con Pembrolizumab in aggiunta a Gemcitabina/Cisplatino verso Placebo in aggiunta a Gemcitabina/Cisplatino come Terapia di prima linea in Partecipanti con Carcinoma del Tratto Biliare in fase avanzata e/o non resecabile

MK7902-002-01 (E7080-G000-311) LEAP-002 - A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination with Pembrolizumab (MK-3475) Versus Lenvatinib in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma

COSMIC XL184-312 - A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy

D910DC00001 EMERALD 2 - A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation

D933RC00001 - A phase III, randomized, open label, multi center, global study to determine the efficacy and safety of Durvalumab in combination with gemcitabine + Cisplatin for neo-adjuvant treatment followed by Durvalumab alone for adjuvant treatment in patients with muscle invasive bladder cancer

CA209-040 - An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer (CheckMate040)

MS200647-0037 - A phase II, multicenter, randomized, open label, controlled study of M7824 versus pembrolizumab as a first line treatment in patients with PDL1 expressing advanced non small cell lung cancer

B9991001 JAVELIN BLADDER 100 - A phase 3, multicenter, multinational, randomized, open-label, parallel-arm study of Avelumab* (MSB0010718C) plus best supportive care versus best supportive care alone as a maintenance treatment in patients with locally advanced or metastatic urothelial cancer whose disease did not progress after completion of first-line platinum-containing chemotherapy.

TALAPRO-2 C3441021 - A phase 3, randomized, double blind, placebo controlled study of Talazoparib with Enzalutamide in metastatic castration-resistant prostate cancer

WO39210 - Studio di fase III, multicentrico, randomizzato in doppio cieco e controllato verso placebo per valutare ATEZOLIZUMAB (ANTICORPO ANTI-PD-L1) come terapia adiuvante in pazienti affetti da IPERNEFROMA a seguito di nefrectomia e ad alto rischio di sviluppare metastasi.

ASC-MAN-P016 - A multicenter, open-label study to evaluate the safety and diagnostic efficacy of Mangoral in patients with known or suspected focal liver lesions and severe renal impairment

RAD-18-TACE - Transarterial embolization alone versus drug-eluting beads chemoembolization for hepatocellular carcinoma. A randomized controlled trial.

R2810-ONC-1788 - Studio randomizzato, in doppio cieco, controllato verso placebo sul trattamento adiuvante con cemiplimab rispetto al placebo dopo intervento chirurgico e radioterapia in pazienti con carcinoma cutaneo a cellule squamose ad alto rischio

SGNLVA-005 - Open-Label Phase 2 Study of Ladiratumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors.

MSD - 3475-A18 - A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (KEYNOTE-A18 / ENGOT-cx11)

MSD - 6482-005 - An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies

MSD - 7339-010 - A Phase 3, Randomized, Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and Chemotherapy (MK7339-010)

MSD - 7902-011 - A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Lenvatinib (E7080/MK-7902) versus Pembrolizumab plus Placebo for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1 (CPS ≥10) and Platinum-ineligible Participants Regardless of PD-L1 Expression

CAAA601A22301 NETTER-2 - Studio di fase III, multicentrico, randomizzato, in aperto volto a valutare l'efficacia e la sicurezza di Lutathera in pazienti con tumori neuroendocrini gastroentero-pancreatici (GEP-NET) di grado 2 e grado 3 in stadio avanzato

DZB-CS-301 - Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification-Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma (FIDES-01)

AXIOMATIC 70033093THR2001 - A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery (AXIOMATIC-TKR)

CA209498 - A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination with Radiation Therapy in Newly Diagnosed Adult Subjects with Unmethylated MGMT (tumor O-6-methylguanine DNA methyltransferase) Glioblastoma

CA209548 - A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6-methylguanine DNA methyltransferase) Glioblastoma

CA209143 - A Randomized Phase IIB Open Label Study of Nivolumab or Nivolumab in Combination with Ipilimumab versus Bevacizumab in Adult Subjects with Recurrent Glioblastoma (GBM)

MO28347 - A double-blind, placebo-controlled, randomized, Phase IIb trial evaluating the efficacy and safety of standard of care (SOC) +/-continuous bevacizumab treatment following progression of disease (PD) in patients with glioblastoma (GBM) after first (1st)-line treatment with radiotherapy, temozolomide and bevacizumab

I3Y-MC-JPBL - MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant with or without Abemaciclib, a CDK4/6 inhibitor, for Women with Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer

I3Y-MC-JPCG - A Randomized, Open-Label, Phase 2 Study of Abemaciclib plus Tamoxifen or Abemaciclib Alone, in Women with Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer

BO27938 - a randomized, multicenter, open-label phase III study to evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy for patients with her2-positive primary breast cancer who have residual tumor present pathologically in the breast or axillary lymph nodes following preoperative therapy

CA209331 - An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects with Relapsed Small-cell Lung Cancer after Platinum-based First Line Chemotherapy

CDX110-04 - An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma

Dichiaro che le informazioni riportate nel presente Curriculum Vitae sono esatte e veritiere.

Autorizzo il trattamento dei dati personali, ivi compresi quelli sensibili, ai sensi e per gli effetti del decreto legge 196/2003 per le finalità di cui al presente avviso di candidatura.

Bologna, 05-03-2021

